Association between body mass index and efficacy of neoadjuvant targeted therapy in HER2-positive breast cancer in a Chinese multicenter cohort

Chengye Hong, Peidong Yang, Debo Chen, Weibin Lian · 2025

Read Association between body mass index and efficacy of neoadjuvant targeted therapy in HER2-positive breast cancer in a Chinese multicenter cohort by Chengye Hong, Peidong Yang, Debo Chen, Weibin Lian (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12657506.txt.

Description

A peer-reviewed research article from Europe PMC (2025). Overweight/Obesity, characterized by body mass index (BMI) ≥ 25 kg/m2, is recognized as a significant prognostic factor in HER2-positive breast cancer, yet its precise influence on neoadjuvant targeted therapy response remains incompletely understood. To address this critical knowledge gap, we conducted a multicentre retrospective cohort study investigating the impact of BMI on pathological complete response (pCR) among HER2-positive breast cancer patients undergoing neoadjuvant targeted therapy. The study comprised 826 Chinese patients from January 2013 to June 2024.

Catalog record

CREATORChengye Hong, Peidong Yang, Debo Chen, Weibin Lian
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12657506

Browse the full library · About the Tower of Babel